Adaptive Biotechnologies Shares Rise on Preliminary Earnings

Dow Jones01-12

By Connor Hart

Shares of Adaptive Biotechnologies climbed after the company reported preliminary fourth-quarter and full-year results.

The stock rose 14% to $18 in premarket trading Monday. Through Friday's close, shares have more than doubled over the past year.

The biotechnology company said before the bell that it expects to report fourth-quarter revenue of $72 million, up 51% from a year earlier. Analysts polled by FactSet were expecting revenue of $59.3 million.

For the year, revenue is projected to come in at $277 million, marking a 55% increase from 2024. Wall Street had modeled full-year revenue of $264.7 million.

Chief Executive Chad Robins called 2025 a pivotal year for the company. Looking ahead, the company expects sales of ClonoSEQ--which helps doctors detect, quantify and monitor small amounts of cancer known as measurable residual disease, or MRD--to continue to accelerate, advancing its leadership in MRD testing, he added.

The company plans to release its complete fourth-quarter and full-year results during an earnings call next month.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 12, 2026 08:27 ET (13:27 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602548578?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602548578","market":"nz","top_or_hot":-1,"title":"Adaptive Biotechnologies Shares Rise on Preliminary Earnings","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> climbed after the company reported preliminary fourth-quarter and full-year results. \n</p>\n<p>\n  The stock rose 14% to $18 in premarket trading Monday. Through Friday's close, shares have more than doubled over the past year. \n</p>\n<p>\n  The biotechnology company said before the bell that it expects to report fourth-quarter revenue of $72 million, up 51% from a year earlier. Analysts polled by FactSet were expecting revenue of $59.3 million. \n</p>\n<p>\n  For the year, revenue is projected to come in at $277 million, marking a 55% increase from 2024. Wall Street had modeled full-year revenue of $264.7 million. \n</p>\n<p>\n  Chief Executive Chad Robins called 2025 a pivotal year for the company. Looking ahead, the company expects sales of ClonoSEQ--which helps doctors detect, quantify and monitor small amounts of cancer known as measurable residual disease, or MRD--to continue to accelerate, advancing its leadership in MRD testing, he added. \n</p>\n<p>\n  The company plans to release its complete fourth-quarter and full-year results during an earnings call next month. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 08:27 ET (13:27 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adaptive Biotechnologies Shares Rise on Preliminary Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdaptive Biotechnologies Shares Rise on Preliminary Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-12 21:27</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> climbed after the company reported preliminary fourth-quarter and full-year results. \n</p>\n<p>\n  The stock rose 14% to $18 in premarket trading Monday. Through Friday's close, shares have more than doubled over the past year. \n</p>\n<p>\n  The biotechnology company said before the bell that it expects to report fourth-quarter revenue of $72 million, up 51% from a year earlier. Analysts polled by FactSet were expecting revenue of $59.3 million. \n</p>\n<p>\n  For the year, revenue is projected to come in at $277 million, marking a 55% increase from 2024. Wall Street had modeled full-year revenue of $264.7 million. \n</p>\n<p>\n  Chief Executive Chad Robins called 2025 a pivotal year for the company. Looking ahead, the company expects sales of ClonoSEQ--which helps doctors detect, quantify and monitor small amounts of cancer known as measurable residual disease, or MRD--to continue to accelerate, advancing its leadership in MRD testing, he added. \n</p>\n<p>\n  The company plans to release its complete fourth-quarter and full-year results during an earnings call next month. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 08:27 ET (13:27 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADPT","symbol_name":"Adaptive Biotechnologies Corp","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602548578","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602548578","pubTimestamp":1768224420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Adaptive Biotechnologies climbed after the company reported preliminary fourth-quarter and full-year results.The stock rose 14% to $18 in premarket trading Monday. Through Friday's close, shares have more than doubled over the past year.The biotechnology company said before the bell that it expects to report fourth-quarter revenue of $72 million, up 51% from a year earlier. Analysts polled by FactSet were expecting revenue of $59.3 million.For the year, revenue is projected to come in at $277 million, marking a 55% increase from 2024. Wall Street had modeled full-year revenue of $264.7 million.Chief Executive Chad Robins called 2025 a pivotal year for the company. Looking ahead, the company expects sales of ClonoSEQ--which helps doctors detect, quantify and monitor small amounts of cancer known as measurable residual disease, or MRD--to continue to accelerate, advancing its leadership in MRD testing, he added.The company plans to release its complete fourth-quarter and full-y","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADPT":"Adaptive Biotechnologies Corp","BK4121":"生命科学工具和服务"},"translate_title":"Adaptive Biotechnologies股价因初步收益上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Adaptive Biotechnologies climbed after the company reported preliminary fourth-quarter and full-year results. \n\n\n  The stock rose 14% to $18 in premarket trading Monday. Through Friday's close, shares have more than doubled over the past year. \n\n\n  The biotechnology company said before the bell that it expects to report fourth-quarter revenue of $72 million, up 51% from a year earlier. Analysts polled by FactSet were expecting revenue of $59.3 million. \n\n\n  For the year, revenue is projected to come in at $277 million, marking a 55% increase from 2024. Wall Street had modeled full-year revenue of $264.7 million. \n\n\n  Chief Executive Chad Robins called 2025 a pivotal year for the company. Looking ahead, the company expects sales of ClonoSEQ--which helps doctors detect, quantify and monitor small amounts of cancer known as measurable residual disease, or MRD--to continue to accelerate, advancing its leadership in MRD testing, he added. \n\n\n  The company plans to release its complete fourth-quarter and full-year results during an earnings call next month. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 08:27 ET (13:27 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602548578","isCrawlerRequest":true}